CBIO ▲ +2.0% - Crescent Biopharma, Inc. $CBIO - Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors 05-OCT-2026 07:30 AM ET